Floatz logo

131 assets in Esophageal Cancer

Therapeutic assets addressing Esophageal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
lb1908
Esophageal Cancer
Legend Biotech USA IncP1C (37)
[Lu-177]-Pnt6555
Esophageal Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyP1C (37)
ly4052031
Esophageal Cancer
Eli Lilly and CompanyP1C (37)
ly4101174
Esophageal Cancer
Eli Lilly and CompanyP1C (37)
Naptumomab Estafenatox
Esophageal Cancer
NeoTX Therapeutics Ltd.P1C (37)
ngm438
Esophageal Cancer
NGM Biopharmaceuticals, IncP1C (37)
ngm831
Esophageal Cancer
NGM Biopharmaceuticals, IncP1C (37)
Obinutuzumab
Esophageal Cancer
NeoTX Therapeutics Ltd.P1C (37)
pf-08046033
Esophageal Cancer
PfizerP1C (37)
pf-08046876
Esophageal Cancer
PfizerP1C (37)
Pimitespib
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.P1C (37)
sh009
Esophageal Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.P1C (37)
Stro-004
Esophageal Cancer
Sutro Biopharma, Inc.P1C (37)
Tas-102
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.P1C (37)
Tas-115
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.P1C (37)
Tbi-1301
Esophageal Cancer
University Health Network, TorontoP1C (37)
tj101
Esophageal Cancer
Phrontline BiopharmaP1C (37)
Vactosertib
Esophageal Cancer
David WaldP1C (37)
[18f]f-resca-g5
Esophageal Cancer
RenJi HospitalN/AD (30)
[18f]f-resca-rb14
Esophageal Cancer
RenJi HospitalN/AD (30)
[18F]F-RESCA-RND20
Esophageal Cancer
RenJi HospitalN/AD (30)
[18F]F-RESCA-T4
Esophageal Cancer
RenJi HospitalN/AD (30)
[18f]f-resca-wwh347
Esophageal Cancer
RenJi HospitalN/AD (30)
[68Ga]Ga-DOTA-H2D3
Esophageal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-g5
Esophageal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-rnd20
Esophageal Cancer
RenJi HospitalN/AD (30)
[68ga]ga-nota-t4
Esophageal Cancer
RenJi HospitalN/AD (30)
[68Ga]Ga-NOTA-WWH347
Esophageal Cancer
RenJi HospitalN/AD (30)
Cabozantinib
Esophageal Cancer
ExelixisP1NR ()
Showing 101 to 131 of 131 assets
PreviousPage 3 of 3Next